Technical Analysis for MYL - Mylan Inc.

Grade Last Price % Change Price Change
grade C 37.81 1.61% 0.60
MYL closed up 1.61 percent on Tuesday, September 18, 2018, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical MYL trend table...

Date Alert Name Type % Chg
Sep 18 Bullish Engulfing Bullish 0.00%
Sep 18 Crossed Above 50 DMA Bullish 0.00%
Sep 18 Pocket Pivot Bullish Swing Setup 0.00%
Sep 18 Oversold Stochastic Weakness 0.00%
Sep 17 50 DMA Resistance Bearish 1.61%
Sep 17 MACD Bearish Centerline Cross Bearish 1.61%
Sep 17 Expansion Pivot Sell Setup Bearish Swing Setup 1.61%
Sep 17 Stochastic Reached Oversold Weakness 1.61%
Sep 17 Lower Bollinger Band Touch Weakness 1.61%
Sep 17 Oversold Stochastic Weakness 1.61%

Older signals for MYL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Mylan Inc. engages in the development, manufacture, marketing, licensing, and distribution of generic and branded generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredients (APIs) worldwide. It operates in two segments, Generics and Specialty. The Generics segment primarily develops, manufactures, sells, and distributes generic or branded generic pharmaceutical products in tablet, capsule, and injectable or transdermal patch forms, as well as API. It also focuses on developing APIs with non-infringing processes to partner with manufacturers. This segment serves proprietary and ethical pharmaceutical wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The Specialty segment manufactures and sells branded specialty injectable, nebulized, and transdermal products for life-threatening conditions. Its products include EpiPen Auto-Injector to treat severe allergic reactions; and Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients. This segment serves pharmaceutical wholesalers and distributors, pharmacies, and healthcare institutions. The company also manufactures and sells injectable products in various therapeutic areas for the hospital setting; supplies APIs for the manufacture of antiretroviral (ARV) drugs to treat HIV/AIDS; offers finished dosage form (FDF) products in the ARV market; and manufactures non-ARV FDF products, as well as focuses on developing, manufacturing, and commercializing dry powder inhaler delivery platform. Mylan Inc. has a strategic collaboration with Pfizer Japan Inc. The company was formerly known as Mylan Laboratories Inc. and changed its name to Mylan Inc. in October 2007. Mylan Inc. was founded in 1961 and is based in Canonsburg, Pennsylvania.
Is MYL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 47.82
52 Week Low 30.69
Average Volume 4,014,659
200-Day Moving Average 39.8754
50-Day Moving Average 37.5952
20-Day Moving Average 38.468
10-Day Moving Average 38.053
Average True Range 0.8508
ADX 14.11
+DI 15.6913
-DI 20.4897
Chandelier Exit (Long, 3 ATRs ) 36.9976
Chandelier Exit (Short, 3 ATRs ) 39.6324
Upper Bollinger Band 39.8432
Lower Bollinger Band 37.0928
Percent B (%b) 0.26
BandWidth 7.149839
MACD Line -0.0906
MACD Signal Line 0.1069
MACD Histogram -0.1975
Fundamentals Value
Market Cap 20.28 Billion
Num Shares 536 Million
EPS 1.24
Price-to-Earnings (P/E) Ratio 30.49
Price-to-Sales 1.72
Price-to-Book 1.61
PEG Ratio 1.59
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.25
Resistance 3 (R3) 39.17 38.62 39.01
Resistance 2 (R2) 38.62 38.25 38.66 38.93
Resistance 1 (R1) 38.21 38.02 38.42 38.29 38.85
Pivot Point 37.66 37.66 37.76 37.70 37.66
Support 1 (S1) 37.25 37.29 37.46 37.33 36.77
Support 2 (S2) 36.70 37.06 36.74 36.69
Support 3 (S3) 36.29 36.70 36.61
Support 4 (S4) 36.37